Clinical Trial Update: Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on a Phase 1/2 study of alvelestat (MPH966), an oral neutrophil elastase inhibitor, for bronchiolitis obliterans syndrome in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiolitis Obliterans Syndrome
• Graft-versus-host Disease

Drugs mentioned

• Alvelestat (alvelestat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING